VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease

Parkinson's Disease

Volumn , Issue , 2011, Pages

  Miller, Gary W ^a,b,c   Taylor, Tonya N ^a,b   Caudle, W Michael ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; VESICULAR MONOAMINE TRANSPORTER 2;

CLINICAL FEATURE; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; LOCUS CERULEUS; MOTOR DYSFUNCTION; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; SYMPTOM;

EID: 79955067247     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.4061/2011/124165     Document Type: Review

References (64)

1. Parkinson J., An Essay on the Shaking Palsy 1817 London, UK Sherwood, Neely, and Jones
2. Olanow C. W., Tatton W. G., Etiology and pathogenesis of Parkinson's disease Annual Review of Neuroscience 1999 22 123 144 (Pubitemid 29144883)
3. Fahn S., Sulzer D., Neurodegeneration and neuroprotection in Parkinson disease NeuroRx 2004 1 1 139 154 (Pubitemid 46589347)
4. Saito M., Maruyama M., Ikeuchi K., Kondo H., Ishikawa A., Yuasa T., Tsuji S., Autosomal recessive juvenile parkinsonism Brain and Development 2000 22 supplement 1 S115 S117
5. Jellinger K., New developments in the pathology of Parkinson's disease Advances in Neurology 1990 53 1 16
6. Jenner P., Olanow C. W., The pathogenesis of cell death in Parkinson's disease Neurology 2006 66 10, supplement 4 S24 S30
7. Braak H., Del Tredici K., Bratzke H., Hamm-Clement J., Sandmann-Keil D., Rb U., Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) Journal of Neurology, Supplement 2002 249 supplement 3 III1 III5
8. Gonera ED. G., Van't Hof M., Berger H. J. C., Van Weel C., Horstink M. W. I. M., Symptoms and duration of the prodromal phase in Parkinson's disease Movement Disorders 1997 12 6 871 876 (Pubitemid 27496762)
9. Ziemssen T., Reichmann H., Non-motor dysfunction in Parkinson's disease Parkinsonism and Related Disorders 2007 13 6 323 332 (Pubitemid 47212791)
10. Caudle W. M., Richardson J. R., Wang M. Z., Taylor T. N., Guillot T. S., McCormack A. L., Colebrooke R. E., Di Monte D. A., Emson P. C., Miller G. W., Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration Journal of Neuroscience 2007 27 30 8138 8148 (Pubitemid 47173329)
11. Jenner P., Hunot., Olanow., Beal., Kordower., Tatton., Schapira., Oxidative stress in Parkinson's disease Annals of Neurology 2003 53 3 S26 S38
12. Surratt C. K., Persico A. M., Yang D. X., Edgar S. R., Bird G. S., Hawkins A. L., Griffin C. A., Li X., Jabs E. W., Uhl G. R., A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs FEBS Letters 1993 318 3 325 330 (Pubitemid 23071763)
13. Erickson J. D., Eiden L. E., Hoffman B. J., Expression cloning of a reserpine-sensitive vesicular monoamine transporter Proceedings of the National Academy of Sciences of the United States of America 1992 89 22 10993 10997
14. Liu Y., Peter D., Roghani A., Schuldiner S., Prive G. G., Eisenberg D., Brecha N., Edwards R. H., A cDNA that suppresses MPP toxicity encodes a vesicular amine transporter Cell 1992 70 4 539 551
15. Forgac M., Structure and function of vacuolar class of ATP-driven proton pumps Physiological Reviews 1989 69 3 765 796 (Pubitemid 19184849)
16. Rudnick G., ATP-driven H pumping into intracellular organelles Annual Review of Physiology 1986 48 403 413
17. Eiden L. E., Schfer M. K. H., Weihe E., Schtz B., The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine Pflugers Archiv 2004 447 5 636 640 (Pubitemid 38241448)
18. Schuldiner S., Shirvan A., Linial M., Vesicular neurotransmitter transporters: from bacteria to humans Physiological Reviews 1995 75 2 369 392
19. Vardy E., Arkin I. T., Gottschalk K. E., Kaback H. R., Schuldiner S., Structural conservation in the major facilitator superfamily as revealed by comparative modeling Protein Science 2004 13 7 1832 1840 (Pubitemid 38822121)
20. Miller G. W., Gainetdinov R. R., Levey A. I., Caron M. G., Dopamine transporters and neuronal injury Trends in Pharmacological Sciences 1999 20 10 424 429 (Pubitemid 29450365)
21. Graham D. G., Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones Molecular Pharmacology 1978 14 4 633 643 (Pubitemid 8402469)
22. Freis E. D., Mental depression in hypertensive patients treated for long periods with large doses of reserpine The New England Journal of Medicine 1954 251 25 1006 1008
23. Peter D., Jimenez J., Liu Y., Kim J., Edwards R. H., The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors Journal of Biological Chemistry 1994 269 10 7231 7237 (Pubitemid 24217912)
24. Schneider J. A., Reserpine antagonism of morphine analgesia in mice Proceedings of the Society for Experimental Biology and Medicine 1954 87 3 614 615
25. Fernagut P. O., Diguet E., Labattu B., Tison F., A simple method to measure stride length as an index of nigrostriatal dysfunction in mice Journal of Neuroscience Methods 2002 113 2 123 130 (Pubitemid 34076535)
26. Skalisz L. L., Beijamini V., Joca S. L., Vital M. A. B. F., Da Cunha C., Andreatini R., Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinson's disease association Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002 26 5 879 883 (Pubitemid 35245553)
27. Silva R. H., Ablio V. C., Torres-Leite D., Bergamo M., Chinen C. C., Claro F. T., Carvalho R. D. C., Frussa-Filho R., Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice Behavioural Brain Research 2002 132 2 171 177 (Pubitemid 34464100)
28. Uhl G. R., Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease Annals of Neurology 1998 43 5 555 560 (Pubitemid 28225546)
29. Liu Y., Edwards R. H., The role of vesicular transport proteins in synaptic transmission and neural degeneration Annual Review of Neuroscience 1997 20 125 156 (Pubitemid 27106378)
30. Kilbourn M. R., DaSilva J. N., Frey K. A., Koeppe R. A., Kuhl D. E., In vivo imaging of vesicular monoamine transporters in human brain using [C]tetrabenazine and positron emission tomography Journal of Neurochemistry 1993 60 6 2315 2318 (Pubitemid 23148808)
31. Miller G. W., Erickson J. D., Perez J. T., Penland S. N., Mash D. C., Rye D. B., Levey A. I., Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease Experimental Neurology 1999 156 1 138 148 (Pubitemid 29152991)
32. Glatt C. E., Wahner A. D., White D. J., Ruiz-Linares A., Ritz B., Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women Human Molecular Genetics 2006 15 2 299 305 (Pubitemid 43125983)
33. Lotharius J., Brundin P., Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein Nature reviews. Neuroscience 2002 3 12 932 942
34. Guo J. T., Chen AN. Q., Kong QI., Zhu H., Ma C. M., Qin C., Inhibition of vesicular monoamine transporter-2 activity in -synuclein stably transfected SH-SY5Y cells Cellular and Molecular Neurobiology 2008 28 1 35 47
35. Mosharov E. V., Staal R. G. W., Bov J., Prou D., Hananiya A., Markov D., Poulsen N., Larsen K. E., Moore C. M. H., Troyer M. D., Edwards R. H., Przedborski S., Sulzer D., -Synuclein overexpression increases cytosolic catecholamine concentration Journal of Neuroscience 2006 26 36 9304 9311 (Pubitemid 44359856)
36. Fon E. A., Pothos E. N., Sun B. C., Killeen N., Sulzer D., Edwards R. H., Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action Neuron 1997 19 6 1271 1283 (Pubitemid 28030546)
37. Wang Y. M., Gainetdinov R. R., Fumagalli F., Xu F., Jones S. R., Bock C. B., Miller G. W., Wightman R. M., Caron M. G., Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine Neuron 1997 19 6 1285 1296 (Pubitemid 28030547)
38. Takahashi N., Miner L. L., Sora I., Ujike H., Revay R. S., Kostic V., Jackson-Lewis V., Przedborski S., Uhl G. R., VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity Proceedings of the National Academy of Sciences of the United States of America 1997 94 18 9938 9943
39. Gainetdinov R. R., Fumagalli F., Wang Y. M., Jones S. R., Levey A. I., Miller G. W., Caron M. G., Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice Journal of Neurochemistry 1998 70 5 1973 1978 (Pubitemid 28207819)
40. Reveron M. E., Savelieval K. V., Tillerson J. L., McCormack A. L., Di Monte D. A., Miller G. W., L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice NeuroToxicology 2002 23 4-5 611 619 (Pubitemid 36527681)
41. Fukui M., Rodriguiz R. M., Zhou J., Jiang S. X., Phillips L. E., Caron M. G., Wetsel W. C., Vmat2 heterozygous mutant mice display a depressive-like phenotype Journal of Neuroscience 2007 27 39 10520 10529 (Pubitemid 47502010)
42. Fumagalli F., Gainetdinov R. R., Wang Y. M., Valenzano K. J., Miller G. W., Caron M. G., Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice Journal of Neuroscience 1999 19 7 2424 2431 (Pubitemid 29162392)
43. Kariya S., Takahashi N., Hirano M., Ueno S., Increased vulnerability to L-DOPA toxicity in dopaminergic neurons from VMAT2 heterozygote knockout mice Journal of Molecular Neuroscience 2005 27 3 277 279 (Pubitemid 41572674)
44. Specht C. G., Schoepfer R., Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice BMC Neuroscience 2001 2, article 11
45. Mooslehner K. A., Pok Man Chan., Xu W., Liu L., Smadja C., Humby T., Allen N. D., Wilkinson L. S., Emson P. C., Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism Molecular and Cellular Biology 2001 21 16 5321 5331 (Pubitemid 32702438)
46. Colebrooke R. E., Humby T., Lynch P. J., McGowan D. P., Xia J., Emson P. C., Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease European Journal of Neuroscience 2006 24 9 2622 2630 (Pubitemid 44726774)
47. Patel J., Mooslehner K. A., Chan P. M., Emson P. C., Stamford J. A., Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice Journal of Neurochemistry 2003 85 4 898 910 (Pubitemid 36578622)
48. Colebrooke R. E., Chan P. M., Lynch P. J., Mooslehner K., Emson P. C., Differential gene expression in the striatum of mice with very low expression of the vesicular monoamine transporter type 2 gene Brain Research 2007 1152 1 10 16 (Pubitemid 46802506)
49. Norris E. H., Giasson B. I., Hodara R., Xu S., Trojanowski J. Q., Ischiropoulos H., Lee V. M. Y., Reversible inhibition of -synuclein fibrillization by dopaminochrome-mediated conformational alterations Journal of Biological Chemistry 2005 280 22 21212 21219 (Pubitemid 40805683)
50. Conway K. A., Rochet J. C., Bieganski R. M., Lansbury P. T., Kinetic stabilization of the -synuclein protofibril by a dopamine- -synuclein adduct Science 2001 294 5545 1346 1349 (Pubitemid 33063102)
51. Tillerson J. L., Caudle W. M., Revern M. E., Miller G. W., Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Experimental Neurology 2002 178 1 80 90 (Pubitemid 35425611)
52. Braak H., Del Tredici K., Rb U., De Vos R. A. I., Jansen Steur E. N. H., Braak E., Staging of brain pathology related to sporadic Parkinson's disease Neurobiology of Aging 2003 24 2 197 211 (Pubitemid 36007810)
53. Lemke M. R., Fuchs G., Gemende I., Herting B., Oehlwein C., Reichmann H., Rieke J., Volkmann J., Depression and Parkinson's disease Journal of Neurology, Supplement 2004 251 supplement 6 VI/24 VI/27
54. Dauer W., Przedborski S., Parkinson's disease: mechanisms and models Neuron 2003 39 6 889 909 (Pubitemid 37130207)
55. Rommelfanger K. S., Weinshenker D., Norepinephrine: the redheaded stepchild of Parkinson's disease Biochemical Pharmacology 2007 74 2 177 190 (Pubitemid 46890808)
56. Taylor T. N., Progressive noradrenergic degeneration precedes nigral cell loss in a mouse model of Parkinson's disease Proceedings of the Annual Meeting of the Society for Neuroscience 2010 San Diego, Calif, USA
57. Langston J. W., The Parkinson's complex: parkinsonism is just the tip of the Iceberg Annals of Neurology 2006 59 4 591 596
58. Doty R. L., Stern M. B., Pfeiffer C., Gollomp S. M., Hurtig H. I., Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease Journal of Neurology Neurosurgery and Psychiatry 1992 55 2 138 142
59. Tissingh G., Booij J., Bergmans P., Winogrodzka A., Janssen A. G. M., Van Royen E. A., Stoof J. C., Wolters E. CH., Iodine-123-N- -fluoropropyl-2/ -carbomethoxy3 -(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease Journal of Nuclear Medicine 1998 39 7 1143 1148 (Pubitemid 28326141)
60. Ward C. D., Hess W. A., Calne D. B., Olfactory impairment in Parkinson's disease Neurology 1983 33 7 943 946 (Pubitemid 13066700)
61. Kranick S. M., Duda J. E., Olfactory dysfunction in Parkinson's disease NeuroSignals 2007 16 1 35 40
62. Taylor T. N., Caudle W. M., Shepherd K. R., Noorian A., Jackson C. R., Iuvone P. M., Weinshenker D., Greene J. G., Miller G. W., Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity Journal of Neuroscience 2009 29 25 8103 8113
63. Swoap S. J., Weinshenker D., Palmiter R. D., Garber G., Dbh(-/-) mice are hypotensive, have altered circadian rhythms, and have abnormal responses to dieting and stress American Journal of Physiology 2004 286 1 R108 R113
64. Heneka M. T., Ramanathan M., Jacobs A. H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., Sastre M., Galldiks N., Zimmer A., Hoehn M., Heiss W. D., Klockgether T., Staufenbiel M., Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice Journal of Neuroscience 2006 26 5 1343 1354 (Pubitemid 43237005)